FOR RESEARCH USE ONLY
Predominantly preclinicalRepair research

TB-500

Thymosin Beta-4 active fragment. Researched for soft-tissue repair, angiogenesis and mobility.

01Cell migration02Soft tissue03Actin dynamics
Molecular signature / tb-500
Structural identity

Synthetic fragment based on the Thymosin Beta-4 active region

Also known as

Thymosin Beta-4 active fragment · Tβ4 fragment

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

TB-500 is a synthetic analogue representing the active region of Thymosin Beta-4 (Tβ4) — a 43-amino-acid regulatory protein expressed in virtually all human and animal cells. It has been studied for cell migration, angiogenesis, stem cell recruitment and the repair of muscle, tendon, ligament, cardiac and neural tissue.

The research question

TB-500 is investigated for its relationship with actin dynamics and cell movement. That gives it a different research emphasis from local cytoprotective compounds: the focus is on how repair cells travel, organise and participate in remodelling.

Section 02

Mechanism & research themes

Sequesters G-actin monomers to regulate actin polymerisation dynamics, driving cell migration, angiogenesis and tissue remodelling. Upregulates MMP-2 and promotes progenitor cell recruitment at injury sites.

01

Accelerated wound and dermal closure in Phase II research

02

Cardiomyocyte survival and repair in post-MI rodent models

03

Enhanced tendon, ligament and fascia recovery

04

Downregulation of TNF-α and IL-1β inflammatory mediators

05

Reduced infarct volume in stroke models; axonal growth support

06

Accelerated corneal epithelial healing in Phase II ocular trials

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Predominantly preclinical

Much of the wider evidence base concerns full-length Thymosin Beta-4 rather than TB-500 itself. Results from one should not be assigned to the other without direct comparative work.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use a 2–2.5mg loading dose twice weekly for 4–6 weeks, followed by 1.5–2mg once weekly for maintenance. Cycles typically run 6–8 weeks with 4-week breaks. Route: subcutaneous or intramuscular.

Reported persistence

Plasma half-life approximately 30–80 minutes for free Tβ4, but SC/IM depot effects extend functional activity over several days per injection.

Calculator starting point

2 mg per reference dose

2 doses per week · 6-week cycle

2 mL default reconstitution volume

Loading: 2–2.5 mg twice weekly for 4–6 weeks, then 1.5–2 mg weekly maintenance.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate TB-500
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Gently swirl; do not vortex.

Storage reference

Lyophilised: 2–8°C for routine storage, or -20°C for long-term (stable 18–24 months). Reconstituted: 2–8°C, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Transient post-injection 'head rush' or fatigue commonly reported, typically resolving within 30–60 minutes.

L2

Class-level caution flagged for subjects with active malignancy due to angiogenic mechanisms.

L3

Most outcome data derives from Tβ4 studies rather than the TB-500 fragment specifically — direct extrapolation requires caution.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only